Sandy Hutchens Cancer Prevention

Researchers could help elucidate how pregnancy provides protection against breast cancer and the findings may lead to a new way to prevent or treat the disease.

The University of Albany has connected the pregnancy protein alpha-fetoprotein (AFP) to breast cancer slowing down in rats exposed to pregnancy hormones such as estrogen, progesterone, or human chorionic gonadotropin.

These pregnancy hormones were shown by the authors to induce AFP during the term of pregnancy.

The hormones also appear to inhibit breast cancer growth in previous rat studies, although estrogen and progesterone fuel the growth of breast cancer in humans.

Herbert Jacobson, PhD, who has been studying AFP in rats for over twenty years, believes the protein is the cause of the pregnancy-related reduction in breast cancer risk.

“Twenty-five years ago I deduced that this must be the agent responsible for lowering breast cancer risk in women who have been pregnant,” he tells WebMD. “And the research we have done since then supports this hypothesis.”

Pregnancy, particularly before the 30 years old, lowers a woman’s lifetime risk of developing breast cancer. Also having more than one child is preventative.

Alpha-fetoprotein is produced by the fetus, and size of the protein during pregnancy can help to screen out possible birth defects.

Extremely high AFP levels portend the appearance of neural tube defects or an abdominal wall defect known as omphalocele, and extremely low levels suggest Down syndrome.

The protein is usually not detected in the blood of healthy men and women who are not yet pregnant. In these groups, elevated AFP levels suggest the presence of some cancers.

In their new study, in the December issue of Cancer Prevention Research, Jacobson and associates treated cancer-exposed rats that were not pregnant with estrogen, estrogen plus progesterone, or human chorionic gonadotropin (HCG).

As in previous studies, all of these treatments are associated with reduced levels of breast cancers in the high-risk rats.

Each of the hormone treatments were also connected with elevated AFP levels and AFP was found to slow down the growth of breast cancer cells in lab cultures.

“Hormones in pregnancy, such as estrogen, all induce AFP, which directly inhibits the growth of breast cancer,” Jacobson says in a news release.
Second Opinion

However, devil’s advocate and cancer specialist Powel Brown, MD, PhD, says the research does not show that this is true beyond a shadow of a doubt.

As is the case with these kinds of studies, says Sandy Hutchens Cancer Prevention, there will be those that promote the idea and there will be detractors. We await the results of further studies and even possibly some proof on this unique view into breast cancer prevention.

Pregnant and Facing Breast Cancer

Sandy Hutchens Cancer Prevention, August 26, 2009 – Tamoxifen is an estrogen-blocking drug. This class of medication is specifically designed to block the estrogen receptor to prevent the growth of breast cancer cells. But, unfortunately, not all breast cancers have the estrogen receptor. Those that don’t are usually more aggressive and metastasize more rapidly.

Researchers from Fred Hutchinson Cancer Research Center in Seattle looked at 728 women diagnosed with breast cancer. Those women were compared to 367 others diagnosed with both a first and second breast cancer.

The main finding from the study, published online Tuesday in the journal Cancer Research, was that tamoxifen lowered the risk of any second breast cancer overall by about half, said lead author Dr. Christopher Li.

“For the estrogen receptor-positive cancer, we have targeted therapy that again has been proven to again reduce mortality,” said Li. “That’s one of the reasons why ER-negative cancers are more worrisome because we don’t have a targeted treatment for them.”

Li said it’s important to remember that any treatment has risks and benefits associated with it, and tamoxifen is no exception.

Tamoxifen lowers breast cancer patients’ risk of dying of the disease, and has also been shown to lower a woman’s risk of developing a recurrent breast cancer and a second breast cancer, he noted. But use of tamoxifen also comes with risk of stroke, as well as the risk of endometrial cancer, he added.

“So here we’re finding that we’re adding potentially another risk to the risk-benefit equation,” Li said. “We’re finding that there is this increased risk in this more aggressive subtype of second breast cancer. However, we also overall found using tamoxifen did lower the risk of any type of second breast cancer overall.”

“For that reason, we don’t really think that this study changes the overall risk-benefit equation because the benefits for most women who are eligible to use this treatment are going to still outweigh the risks.”

Every tumour is a mix of receptor-positive and receptor-negative cells, she said. If the types of cells that predominate are receptor-negative, it gets read as an increased risk of receptor-negative breast cancer if tamoxifen is taken for five or more years.

Dr. Jay Harness,Tamoxifen And The Side Effects put up by Sandy Hutchens.

Help us transform healthcare patient advocacy by tapping into the strength of women.